BeiGene EBITDA Margin 2014-2024 | ONC
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for BeiGene (ONC) over the last 10 years. The current EBITDA margin for BeiGene as of September 30, 2024 is .
| BeiGene EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$3.32B |
$-0.73B |
-21.92% |
| 2024-06-30 |
$3.10B |
$-0.79B |
-25.52% |
| 2024-03-31 |
$2.76B |
$-1.00B |
-36.35% |
| 2023-12-31 |
$2.46B |
$-1.12B |
-45.52% |
| 2023-09-30 |
$2.20B |
$-1.21B |
-54.90% |
| 2023-06-30 |
$1.81B |
$-1.52B |
-83.93% |
| 2023-03-31 |
$1.56B |
$-1.65B |
-105.78% |
| 2022-12-31 |
$1.42B |
$-1.72B |
-121.67% |
| 2022-09-30 |
$1.25B |
$-1.83B |
-146.44% |
| 2022-06-30 |
$1.07B |
$-1.86B |
-173.99% |
| 2022-03-31 |
$0.88B |
$-1.90B |
-216.53% |
| 2021-12-31 |
$1.18B |
$-1.39B |
-118.37% |
| 2021-09-30 |
$1.06B |
$-1.31B |
-123.35% |
| 2021-06-30 |
$0.95B |
$-1.29B |
-136.43% |
| 2021-03-31 |
$0.86B |
$-1.18B |
-136.73% |
| 2020-12-31 |
$0.31B |
$-1.63B |
-526.21% |
| 2020-09-30 |
$0.27B |
$-1.53B |
-575.19% |
| 2020-06-30 |
$0.23B |
$-1.41B |
-624.89% |
| 2020-03-31 |
$0.40B |
$-1.14B |
-282.84% |
| 2019-12-31 |
$0.43B |
$-0.94B |
-219.86% |
| 2019-09-30 |
$0.43B |
$-0.84B |
-194.65% |
| 2019-06-30 |
$0.43B |
$-0.68B |
-156.22% |
| 2019-03-31 |
$0.24B |
$-0.76B |
-310.25% |
| 2018-12-31 |
$0.20B |
$-0.70B |
-349.75% |
| 2018-09-30 |
$0.16B |
$-0.52B |
-329.75% |
| 2018-06-30 |
$0.32B |
$-0.26B |
-79.01% |
| 2017-09-30 |
$0.22B |
$-0.03B |
-13.18% |
| 2016-12-31 |
$0.00B |
$-0.12B |
-11500.00% |
| 2016-06-30 |
$0.01B |
$-0.08B |
-1085.71% |
| 2016-03-31 |
$0.01B |
$-0.06B |
-762.50% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
